Oncology · Phase II

Top sponsors

• First People's Hospital 261 programs
• Chinese Academy of 198 programs
• George Institute for 118 programs
• United Therapeutics Europe 112 programs
• Telethon Foundation 91 programs
• Takeda 79 programs
• Regeneron UK 71 programs
• MSD Merck Sharp 63 programs
• Ningbo Cancer Hospital 62 programs
• Anaxis Pharma 57 programs
• AstraZeneca 52 programs
• HOFFMANN-LA ROCHE 50 programs

1. IB 2021-01

   The George Institute

   Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

   phase 2 · small molecule · active

   1 trial →

2. IB 2021-03

   The George Institute

   Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

   phase 2 · small molecule · active

   1 trial →

3. IB 2023-02

   The George Institute

   Adult patients with locally advanced/metastatic solid tumors

   phase 2 · small molecule · active

   1 trial →

4. IBB0979

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Small Cell Lung Cancer

   phase 2 · small molecule · active

   1 trial →

5. IBB0979

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Advanced Malignant Tumors

   phase 2 · small molecule · active

   1 trial →

6. IBI363

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Non Small Cell Lung Cancer

   phase 2 · small molecule · active

   1 trial →

7. IBRUTINIB

   Fondazione Telethon ETS

   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis

   phase 2 · small molecule · active

   1 trial →

8. IC 2019-02

   The George Institute

   Primary Central Nervous System Lymphoma (PCNSL)

   phase 2 · other · active

   1 trial →

9. IC 2020-06

   The George Institute

   Metastatic uveal melanoma

   phase 2 · other · active

   1 trial →

10. IC 2022-07

    The George Institute

    Breast cancer

    phase 2 · small molecule · active

    1 trial →

11. IC 2024-01

    The George Institute

    HER3-mutant and HER2-not amplified metastatic breast cancer

    phase 2 · small molecule · active

    1 trial →

12. ICO-2023-10

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 · small molecule · active

    1 trial →

13. ICO-2023-14

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 · small molecule · active

    1 trial →

14. ICO-N-2013-03

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 · small molecule · active

    1 trial →

15. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 · small molecule · active

    1 trial →

16. IDE196-009

    IDEAYA Biosciences

    Uveal Melanoma

    phase 2 · small molecule · active

    1 trial →

17. IDE574

    IDEAYA Biosciences

    ER+, HER 2- Breast Cancer

    phase 2 · small molecule · active

    1 trial →

18. IDE849

    IDEAYA Biosciences

    Small-cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

19. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Unresectable/metastatic Small cell Lung Cancer (SCLC)

    phase 2 · small molecule · active

    1 trial →

20. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Chronic lymphocytic leukemia (CLL), Any type of B-cell lymphomas, Multiple myeloma (MM)

    phase 2 · small molecule · active

    1 trial →

21. IFCT-1904

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

22. IFCT-2003

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced ROS1-positive non-small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

23. IFCT-2101

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

24. IFCT-2401 SPORADIC

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

25. IFCT-2502

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 · small molecule · active

    1 trial →

26. IFG-05-2019

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 · small molecule · active

    1 trial →

27. IFOM-CPT008/2022/PO0

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 · small molecule · active

    1 trial →

28. IGEV

    Fudan University

    Hodgkin Lymphoma

    phase 2 · small molecule · active

    1 trial →

29. IIT2024097

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 2 · small molecule · active

    1 trial →

30. IJB-LBC-NEOCHECK2018

    The George Institute

    Luminal B Breast Cancer

    phase 2 · small molecule · active

    1 trial →

31. IJB-REGINA-2020

    The George Institute

    Locally-advanced stage II-III rectal cancer

    phase 2 · small molecule · active

    1 trial →

32. IJB-SYNERGY-012017

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 · small molecule · active

    1 trial →

33. IJB-ZEPHIR02-2024

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 · small molecule · active

    1 trial →

34. IJB-ZEPHIR02-2024

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 · small molecule · active

    1 trial →

35. IKF/AIO-ZANGEA

    The George Institute

    Gastroesophageal Adenocarcinoma

    phase 2 · small molecule · active

    1 trial →

36. IMC-R117C

    Immunocore Ireland Limited

    Cancer

    phase 2 · small molecule · active

    1 trial →

37. IMCgp100-202

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 · small molecule · active

    1 trial →

38. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 · small molecule · active

    1 trial →

39. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 · small molecule · active

    1 trial →

40. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy

    phase 2 · small molecule · active

    1 trial →

41. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously untreated

    phase 2 · small molecule · active

    1 trial →

42. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)

    phase 2 · small molecule · active

    1 trial →

43. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients With Muscle-Invasive Bladder Cancer

    phase 2 · small molecule · active

    1 trial →

44. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

45. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 · small molecule · active

    1 trial →

46. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    unresectable stage III NSCLC (Non–small-cell lung cancer)

    phase 2 · small molecule · active

    1 trial →

47. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    oligometastatic hormone sensitive prostate cancer

    phase 2 · small molecule · active

    1 trial →

48. IMFINZI for Metastatic pancreatic cancer

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 · small molecule · active

    1 trial →

Frequently asked questions